Clinical Trial Design for Alcoholic Hepatitis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Alcoholic hepatitis (AH) is an acute and clinically distinct manifestation of alcoholic liver disease. While severe AH causes 30% or higher mortality in 3 months, treatment options are limited and ineffective. Recent advances on the understanding of the pathomechanisms of AH have identified numerous potential targets for new therapeutic interventions. Many of those targets are currently under preclinical testing and/or in human clinical trials for nonalcoholic steatohepatitis. Thus, the field of AH should be ready to launch new efforts and targeted clinical trials for this underserved patient population. There are remaining challenges in designing clinical trials in AH that include definition of the severity of disease, common data elements in clinical trial design, and selection of clinically meaningful endpoints. Future efforts and consensus meetings between regulatory agencies, academic and clinical experts, and industry will be instrumental to advance this emerging and greatly needed field of clinical investigations.

Original languageEnglish
Pages (from-to)332-342
Number of pages11
JournalSeminars in Liver Disease
Volume37
Issue number4
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Alcoholic Hepatitis
Clinical Trials
Vulnerable Populations
Alcoholic Liver Diseases
Industry
Mortality
Therapeutics

Keywords

  • alcoholic liver disease
  • common data elements
  • endpoints

ASJC Scopus subject areas

  • Hepatology

Cite this

Clinical Trial Design for Alcoholic Hepatitis. / Szabó, G.

In: Seminars in Liver Disease, Vol. 37, No. 4, 01.11.2017, p. 332-342.

Research output: Contribution to journalArticle

@article{61c154fc4d054bc298eb20f22481db9d,
title = "Clinical Trial Design for Alcoholic Hepatitis",
abstract = "Alcoholic hepatitis (AH) is an acute and clinically distinct manifestation of alcoholic liver disease. While severe AH causes 30{\%} or higher mortality in 3 months, treatment options are limited and ineffective. Recent advances on the understanding of the pathomechanisms of AH have identified numerous potential targets for new therapeutic interventions. Many of those targets are currently under preclinical testing and/or in human clinical trials for nonalcoholic steatohepatitis. Thus, the field of AH should be ready to launch new efforts and targeted clinical trials for this underserved patient population. There are remaining challenges in designing clinical trials in AH that include definition of the severity of disease, common data elements in clinical trial design, and selection of clinically meaningful endpoints. Future efforts and consensus meetings between regulatory agencies, academic and clinical experts, and industry will be instrumental to advance this emerging and greatly needed field of clinical investigations.",
keywords = "alcoholic liver disease, common data elements, endpoints",
author = "G. Szab{\'o}",
year = "2017",
month = "11",
day = "1",
doi = "10.1055/s-0037-1608788",
language = "English",
volume = "37",
pages = "332--342",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Clinical Trial Design for Alcoholic Hepatitis

AU - Szabó, G.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Alcoholic hepatitis (AH) is an acute and clinically distinct manifestation of alcoholic liver disease. While severe AH causes 30% or higher mortality in 3 months, treatment options are limited and ineffective. Recent advances on the understanding of the pathomechanisms of AH have identified numerous potential targets for new therapeutic interventions. Many of those targets are currently under preclinical testing and/or in human clinical trials for nonalcoholic steatohepatitis. Thus, the field of AH should be ready to launch new efforts and targeted clinical trials for this underserved patient population. There are remaining challenges in designing clinical trials in AH that include definition of the severity of disease, common data elements in clinical trial design, and selection of clinically meaningful endpoints. Future efforts and consensus meetings between regulatory agencies, academic and clinical experts, and industry will be instrumental to advance this emerging and greatly needed field of clinical investigations.

AB - Alcoholic hepatitis (AH) is an acute and clinically distinct manifestation of alcoholic liver disease. While severe AH causes 30% or higher mortality in 3 months, treatment options are limited and ineffective. Recent advances on the understanding of the pathomechanisms of AH have identified numerous potential targets for new therapeutic interventions. Many of those targets are currently under preclinical testing and/or in human clinical trials for nonalcoholic steatohepatitis. Thus, the field of AH should be ready to launch new efforts and targeted clinical trials for this underserved patient population. There are remaining challenges in designing clinical trials in AH that include definition of the severity of disease, common data elements in clinical trial design, and selection of clinically meaningful endpoints. Future efforts and consensus meetings between regulatory agencies, academic and clinical experts, and industry will be instrumental to advance this emerging and greatly needed field of clinical investigations.

KW - alcoholic liver disease

KW - common data elements

KW - endpoints

UR - http://www.scopus.com/inward/record.url?scp=85039157955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039157955&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1608788

DO - 10.1055/s-0037-1608788

M3 - Article

C2 - 29272895

AN - SCOPUS:85039157955

VL - 37

SP - 332

EP - 342

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -